Psy5 the Usefulness of Registry Data for Understanding Treatment Practices and Clinical Outcomes in Hemophilia: The Experience of the Hemophilia and Thrombosis Research Society (Htrs) Registry (2004–2008)

Kessler, C. M.; Gill, JC; Cooper, D. J.

doi:10.1016/s1098-3015(10)73715-3

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous data collected between 2000 and 2004 from the HTRS registry, which captured dosing information from investigators at similarly large HTC sites and was limited to doses reported to the HTC, showed a median total rFVIIa dose of 360 mcg kg −1 used per bleeding episode, which was administered in a median of 4.0 injections [12]. Initial dose, mean dose per episode, total dose per episode and number of doses in this study were higher than the median overall data reported from the HTRS registry (212 vs. 120 mcg kg −1 , 146 vs. 113 mcg kg −1 , 695 vs. 450 mcg kg −1 and 5 vs. 3 doses)[13]. The DOSE study reported a median initial dose of 211.6 mcg kg −1 with median total dose of 694.9 mcg kg −1 administered in a median of 5.0 injections for each bleeding episode.…”

Section: Discussionmentioning

confidence: 89%

See 1 more Smart Citation

Patient/Caregiver‐reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE)

et al. 2011

View full text Add to dashboard Cite

Patients with congenital haemophilia with inhibitors experience acute bleeds managed with bypassing agents, such as recombinant FVIIa (rFVIIa). Home-based treatment and dosing patterns in the US remain poorly described. This study aimed to assess the prescribed and actual rFVIIa dosing in frequently bleeding inhibitor patients (≥4 bleeds in 3 months) prescribed first-line therapy with rFVIIa. Patients or caregivers recorded daily diaries, including the details of all bypassing agent infusions for 3-6 months. Median (range) initial rFVIIa dose prescribed for joint, muscle and other bleeds was 167.5 (61.0-289.0) mcg kg(-1). Additional rFVIIa doses prescribed were 90 (61-270) mcg kg(-1) at an interval of 2.5-3 (1-24) h. The actual initial rFVIIa dose reported by patients/caregivers for 158 bleeds was 212 (59-400) mcg kg(-1), with total dose per episode of 695 (74-21257) mcg kg(-1). Patient/caregiver-reported average dose per bleed was 146 (40-400) mcg kg(-1) across 5 (1-106) infusions. The initial rFVIIa dose was higher for haemarthrosis (223 [59-400] mcg kg(-1)) than muscle bleeds (148 [74-300] mcg kg(-1); P = 0.07). Initial and mean dose per day changed as treatment progressed. The DOSE study indicates that frequently bleeding inhibitor patients are prescribed and use higher rFVIIa dosing for all bleed types than recommended in the package insert (90 mcg kg(-1)). The rFVIIa dosing was highly variable within and across bleed types, with higher initial doses used for joint bleeds than muscle and other bleed types, particularly in the first days of treatment. This suggests that patients/caregivers have adopted home treatment strategies based on physician discretion and individual responses and experience.

show abstract

Section: Discussionmentioning

confidence: 89%

“…Of enrolled patients, 37 were treated on-demandonly, with 12 on bypassing agent prophylaxis and 5 on concurrent immune tolerance (with or without bypassing agent prophylaxis). The enrolled patients who did not complete diaries (13) were all in the on-demand-only treatment group.…”

Section: Patient Demographicsmentioning

confidence: 99%